Depression Clinical Trial
Official title:
Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression
People who have depression often have symptoms besides sad mood. Cognitive symptoms, such as poor memory, concentration, and decision making, are associated with disability in many spheres of life, and these symptoms often persist even when antidepressant treatment improves other symptoms (mood, energy, sleep, anxiety). Antidepressants alone fail to produce full remission for many patients, so it is important to study adjunctive treatments which can be added onto medication treatment and help restore cognitive function. The method of transcranial direct current stimulation (tDCS) has been shown by others to improve working memory and cognitive functions, and also to help with other symptoms of depression. tDCS involves passing a small, constant current between saline-moistened pads placed on the scalp. In this proposed study, 20 individuals with major depression who have cognitive difficulties despite taking antidepressants will participate. Over the course of a two-week period, each person will receive 5 sessions of either active tDCS or inactive treatments, in addition to their medication. Each session lasts for 20 minutes, and will be administered on alternating days (M-W-F). Assessments of depressive symptoms, cognitive function, and brain activity will be made prior to any sessions, after the first one, and after the fifth (final) session; brain function will be assessed by measuring the brain's electrical activity ("brain waves").
Transcranial direct current stimulation (tDCS), also sometimes termed "DC polarization" or
"brain polarization," is a non-invasive procedure that has been used successfully as a
therapeutic intervention in a number of patient populations. tDCS involves the passing of
very weak currents through an area of interest of the brain, by placing electrodes on the
scalp at the appropriate locations. DC polarization has been shown to alter the amplitude of
evoked potentials in the visual cortex (Antal et al., 2004), and cortical processing in the
parietal lobe also can be modulated by tDCS (Rogalewski et al., 2004). From a more
physiologically-relevant perspective, tDCS of the motor cortex has been shown to improve
motor function in patients following stroke (Hummel and Cohen, 2005; Hummel et al., 2006;
Boggio et al., 2006b) when applied to the prefrontal cortex. tDCS has been shown to improve
working memory in healthy individuals (Fregni et al., 2005b), and in individuals with major
depressive episode. In MDD it has more recently been shown to improve depression rating
self-report scores (Fregni et al., 2006a) and cognitive performance (Fregni et al., 2006b).
Performance on a executive function task (go/no-go) was also shown to be enhanced with tDCS
in adults with MDD (Boggio et al., 2006a). tDCS has been evaluated in subjects with
Parkinson's disease and found to have therapeutics benefit (compared with inactive
treatment) on the Unified Parkinson's Disease Rating Scale and neuropsychological measures
(reaction time, pegboard task) as well as motor evoked potentials (Fregni et al., 2006c).
Several recent studies have affirmed the safety of tDCS. Iyer and colleagues (2005) showed
that, in a sample of 103 subjects, no one asked for the tDCS procedure to be stopped due to
discomfort. Gandiga and colleagues (2006) compared sham to active tDCS and showed no
differences in self-report ratings of discomfort. Nitsche and colleagues (2004) performed
structural MRI scans on healthy individuals who underwent 1 hour exposures to tDCS; they
found no evidence of structural change in the brain or alterations in blood-brain barrier
permeability.
With regard to persistent challenges in the management of MDD, individuals with depression
have shown cognitive deficits, particularly in working memory and other frontal lobe
functions (Dunkin et al., 2000; Sweeney et al., 2000 Jaeger et al., 2006; Rose and Ebmeier
2006; Rose et al., 2006) and declarative memory (e.g., Beaden et al., 2006). By improving
cognitive function in subjects with cognitive complaints that persist despite
pharmacotherapy, it may be possible to improve the completeness of recovery from depression
and reduce any functional disability (Jaeger et al., 2006).
There are no published reports yet of the effects of tDCS on brain function in subjects with
MDD. Cordance is a quantitative electroencephalography (QEEG) measure which allows for
non-invasive measurement of regional brain function (Leuchter et al., 1994a, 1994b, 1999;
Cook et al., 1998). It is sensitive to changes in brain function in subjects who are
responding to treatment for MDD (Cook and Leuchter 2001; Cook et al., 2002, 2005; Leuchter
et al., 2002) and is being evaluated for use a a biomarker which predicts treatment outcome
in MDD (NIMH Project R01MH069217, Cook PI). It is well suited to evaluating brain function
in subjects with MDD during a clinical trial experiment.
Our hypotheses are
1. Subjects who are randomized to receive active tDCS treatments will show greater
improvement in cognitive task performance than subjects who receive inactive
treatments.
2. Subjects who are randomized to receive active tDCS treatments will show greater
improvement in depression symptom severity scores than subjects who receive inactive
treatments.
3. Subjects who are randomized to receive active tDCS treatments will show greater changes
in prefrontal brain function, as assessed with quantitative EEG cordance, than subjects
who receive inactive treatments.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |